KRT-232-115

KRT-232-115: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Enquire

Trial overview

Disease

Haematology

Topic

Myleofibrosis

Sponsor

Kartos Therapeutics

Description

KRT-232-115: A Front-Line, Phase 3, Randomized, Double-Blind, Add-On Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Myelofibrosis Patients Who Have a Suboptimal Response to Ruxolitinib

Study details

details to follow

Trial status

Due to open October 24 in Oxford and Windsor

Location

Oxford Windsor

Priniciple Investigator

Dr Bethan Psalia - Oxford

Dr Pratap Neelakatan - Windsor